Eleri J Williams1, Joanne Gray2, Suzanne Luck3, Claire Atkinson4, Nicholas D Embleton5, Seilesh Kadambari6, Adrian Davis7, Paul Griffiths4, Mike Sharland6, Janet E Berrington5, Julia E Clark8. 1. Department of Paediatric Immunology and Infectious Diseases, Great North Children's Hospital, Royal Victoria Hospital, Newcastle-upon-Tyne, UK Newcastle Neonatal Service, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK. 2. Faculty of Health and Life Sciences, Northumbria University, Newcastle-upon-Tyne, UK. 3. Centre for Virology (Royal Free), University College London Medical School, London, UK Department of Paediatrics, Kingston Hospitals NHS Foundation Trust, London, UK. 4. Centre for Virology (Royal Free), University College London Medical School, London, UK. 5. Newcastle Neonatal Service, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK. 6. Paediatric Infectious Diseases Research Group, St George's, University Hospital of London, London, UK. 7. Public Health England, London, UK. 8. Department of Paediatric Immunology and Infectious Diseases, Great North Children's Hospital, Royal Victoria Hospital, Newcastle-upon-Tyne, UK Department of Paediatric Infectious Diseases, Lady Cilento Children's Hospital, Brisbane, Queensland Australia University of Queensland, Brisbane, Australia.
Abstract
BACKGROUND: Congenital cytomegalovirus (cCMV) is an important cause of childhood deafness, which is modifiable if diagnosed within the first month of life. Targeted screening of infants who do not pass their newborn hearing screening tests in England is a feasible approach to identify and treat cases to improve hearing outcome. AIMS: To conduct a cost analysis of targeted screening and subsequent treatment for cCMV-related sensorineural hearing loss (SNHL) in an, otherwise, asymptomatic infant, from the perspective of the UK National Health Service (NHS). METHODS: Using data from the newborn hearing screening programme (NHSP) in England and a recent study of targeted screening for cCMV using salivary swabs within the NHSP, we estimate the cost (in UK pounds (£)) to the NHS. The cost of screening (time, swabs and PCR), assessing, treating and following up cases is calculated. The cost per case of preventing hearing deterioration secondary to cCMV with targeted screening is calculated. RESULTS: The cost of identifying, assessing and treating a case of cCMV-related SNHL through targeted cCMV screening is estimated to be £6683. The cost of improving hearing outcome for an infant with cCMV-related SNHL through targeted screening and treatment is estimated at £14 202. CONCLUSIONS: The costs of targeted screening for cCMV using salivary swabs integrated within NHSP resulted in an estimate of cost per case that compares favourably with other screening programmes. This could be used in future studies to estimate the full economic value in terms of incremental costs and incremental health benefits. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Congenital cytomegalovirus (cCMV) is an important cause of childhood deafness, which is modifiable if diagnosed within the first month of life. Targeted screening of infants who do not pass their newborn hearing screening tests in England is a feasible approach to identify and treat cases to improve hearing outcome. AIMS: To conduct a cost analysis of targeted screening and subsequent treatment for cCMV-related sensorineural hearing loss (SNHL) in an, otherwise, asymptomatic infant, from the perspective of the UK National Health Service (NHS). METHODS: Using data from the newborn hearing screening programme (NHSP) in England and a recent study of targeted screening for cCMV using salivary swabs within the NHSP, we estimate the cost (in UK pounds (£)) to the NHS. The cost of screening (time, swabs and PCR), assessing, treating and following up cases is calculated. The cost per case of preventing hearing deterioration secondary to cCMV with targeted screening is calculated. RESULTS: The cost of identifying, assessing and treating a case of cCMV-related SNHL through targeted cCMV screening is estimated to be £6683. The cost of improving hearing outcome for an infant with cCMV-related SNHL through targeted screening and treatment is estimated at £14 202. CONCLUSIONS: The costs of targeted screening for cCMV using salivary swabs integrated within NHSP resulted in an estimate of cost per case that compares favourably with other screening programmes. This could be used in future studies to estimate the full economic value in terms of incremental costs and incremental health benefits. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Audiology; Costing; General Paediatrics; Infectious Diseases; Virology
Authors: Kyle T Fletcher; Erin M Wolf Horrell; John Ayugi; Catherine Irungu; Maria Muthoka; Liza M Creel; Cathy Lester; Matthew L Bush Journal: Otol Neurotol Date: 2018-08 Impact factor: 2.311
Authors: Shannon A Ross; Amina Ahmed; April L Palmer; Marian G Michaels; Pablo J Sánchez; Audra Stewart; David I Bernstein; Kristina Feja; Karen B Fowler; Suresh B Boppana Journal: J Pediatr Date: 2017-02-22 Impact factor: 4.406
Authors: Soren Gantt; David M Goldfarb; Albert Park; William Rawlinson; Suresh B Boppana; Tiziana Lazzarotto; Lawrence M Mertz Journal: J Clin Microbiol Date: 2020-03-25 Impact factor: 5.948
Authors: Ethan D Borre; Mohamed M Diab; Austin Ayer; Gloria Zhang; Susan D Emmett; Debara L Tucci; Blake S Wilson; Kamaria Kaalund; Osondu Ogbuoji; Gillian D Sanders Journal: EClinicalMedicine Date: 2021-05-08